Cancer-driven cytokine immunomodulation ameliorates cardiac function and suppresses fibrosis

Area of Science:

• Immunology
• Cardiovascular Biology
• Oncology

Background:

• Heart failure is a major global health challenge with limited therapeutic options.
• Tumor growth has been observed to improve cardiac function and reduce fibrosis in heart failure models.
• The underlying mechanisms of this host-tumor interaction require elucidation for therapeutic application.

Purpose of the Study:

• To investigate the therapeutic potential of serum from tumor-bearing mice in heart failure.
• To identify the key molecular mediators and cellular pathways involved in tumor-induced cardiac repair.
• To establish a novel therapeutic strategy for heart failure and fibrotic conditions.

Main Methods:

• Administration of serum from tumor-bearing mice to mouse models of heart failure.
• Assessment of cardiac function (left-ventricular fractional shortening) and fibrosis.
• Cytokine profiling to identify key mediators (IFNγ, TNFα).
• Investigation of the role of natural killer (NK) cells and macrophages via depletion studies.

Main Results:

• Serum injection significantly improved cardiac function and reduced fibrosis in multiple organs.
• Interferon-gamma (IFNγ) and Tumor Necrosis Factor-alpha (TNFα) were identified as essential mediators.
• Recombinant IFNγ and TNFα mimicked the serum's beneficial effects.
• Macrophages were shown to be critical for the therapeutic response, polarized to an anti-inflammatory state.

Conclusions:

• A novel NK cell-macrophage cytokine axis drives cardiac repair and fibrosis resolution.
• This axis, activated by tumor-derived factors, represents a promising therapeutic avenue for heart failure.
• Harnessing innate immunity offers a new strategy for treating heart failure and fibrotic diseases.